BACKGROUND: Translocation of phosphatidylserine from the inner leaflet to the outer leaflet of the endothelial membrane via phospholipid scramblase-1 (PLSCR1) is an apoptotic signal responsible for the loss of endothelial barrier integrity after ischemia-reperfusion injury (IRI). We hypothesized that inhibiting phosphatidylserine expression on endothelial cells would attenuate IRI induced increases in hydraulic permeability (L p ).
P ostinjury endothelial dysfunction is linked to molecular changes that occur at the lipid membrane. Phosphatidylserine (PS) is a normally appearing lipid substrate that is relegated to the inner cytosolic leaflet of lipid bilayer. This lipid asymmetry in the cell wall bilayer is maintained by an ATP-dependent aminophospholipid translocator that returns exteriorized PS against its concentration gradient to the inner cytosolic leaflet in healthy cells. It is postulated that PS is exteriorized to the outer leaflet during pro-inflammatory states 1 and that PS exposure is thought to act as an apoptotic signal that prompts phagocytes to engulf senescent cells. Phosphatidylserine exteriorization occurs partially via membrane "scramblases," most notably phospholipid scramblase isoform-1 (PLSCR1) and under ATP-depleted states, increased PLSCR1 activity is observed. 2 Additionally, when ATP is depleted, the ATP-dependent aminophospholipid translocator activity becomes less efficient with the end result of increased levels of PS exposed on the outer leaflet of the cell membrane. A proposed mechanism of increased transendothelial flux is exteriorization of PS by PLSCR1, leading to scavenging of damaged endothelial cells, loss of the endothelial barrier and increased efflux of extracellular fluid. Endothelial dysfunction promoting extravascular fluid losses can predispose severely injured patients to multiple organ system failure and sepsis.
Phosphatidylserine exposure has been linked to multiple pathologies, such as HIV infection, 3 sepsis, 4,5 immunologic function and axon degeneration in the CNS, 6 ,7 mast cell degranulation, 8 autoimmune disease, 9 coagulopathy, 10 and malignancy. 11 Phosphatidylserine has been studied extensively at the red blood cell level, specifically in models of sickle cell anemia. 12, 13 In endothelial cells, PS exposure occurs during the systemic capillary leak syndrome 14 and lipopolysaccharide-induced myocardial damage in cardiac endothelium. 15 In models of hypoxia-reoxygenation, PS exposure is linked to IgM binding and promulgation of the inflammatory response. 16 In intestinal ischemia-reperfusion injury (IRI), PS exposure promotes intestinal hyperpermeability. 17 Transmembrane exposure of PS causes complement activation in vitro after hypoxia-reoxygenation, producing further inflammation and vascular injury. 18 Because apoptosis of endothelial cells is thought to be one mechanism of microvascular dysfunction after IRI, 19, 20 our hypothesis was that inhibiting PS expression on endothelial cells would attenuate IRI induced increases in hydraulic permeability (L p ). Hydraulic permeability is a measure that describes the ease by which water moves across the endothelial barrier, which can be dramatically increased during times of physiologic stress. It is derived from the Starling equation which takes into account factors that impact on trans-endothelial water movement such as hydrostatic pressure and oncotic pressure. Our specific aims were to describe changes in L p after IRI using (1) 
MATERIALS AND METHODS
All studies were approved by our Institutional Committee for the use of animals in research and complied with animal research protocols.
Animal Experiments Animal and Solution Preparations
Red blood cells that are used as flow markers were harvested from female Sprague-Dawley rats (250-310 g; Hilltop Lab Animals, Scottsdale, PA). The blood was centrifuged to remove the plasma and buffy coat, and then washed three times in 15 mL of Ringer's solution. The Ringer's solution was prepared daily in distilled deionized water and contained 135 mM NaCl; 4.6 mM KCl; 2.0 mM CaCl; 2.46 mM MgSO 4 ; 5.0 mM NaHCO 3 ; 5.5 mM Dextrose; 9.03 mM Hepes Salt (Research Organics, Cleveland, OH); 11.04 mM Hepes Acid (Research Organics). A 1% bovine serum albumin (fraction V, fatty acid free -Pierce Biotechnology, Rockford IL) Ringer's solution was prepared before each experiment by adding the appropriate amount of BSA to the Ringer's. This was used as the perfusate.
Adult female Sprague-Dawley rats were anesthetized with subcutaneous sodium pentobarbital (60 mg/kg body weight). A midline laparotomy incision was performed. The bowel mesentery was gently exposed and positioned on an inverted microscope stage (Diaphot, Nikon; Melville, NY). The superior mesenteric artery (SMA) was identified at the base of the mesentery and a prolene monofilament suture was placed about it circumferentially for occlusion. Throughout this process the animal's body temperature was maintained at 37°C, and the mesentery was continuously bathed in Ringer's solution.
In Vivo Measurement of L p
Postcapillary venules, 20 μm to 30 μm in diameter and at least 400 μm in length, were identified based on flow patterns. Vessels with no evidence of leukocyte adherence or side branches were chosen. The vessels were cannulated with micropipettes attached to a water manometer to control hydrostatic perfusion pressure.
Single vessel L p was determined using the modified Landis micro-occlusion technique. 21 The assumptions and limitations of this technique have been previously described. 22 Briefly, initial cell velocity (dl/dt) was obtained by recording marker cell position as a function of time. Transmural water flux per unit area (Jv/S) was calculated by the equation: J v /S = (dl/dt) Â (r/21), where r is the capillary radius and 1 is the initial distance between the marker cell and the occluded site. Hydraulic permeability was determined by using a modified version of Starling's equation of fluid filtration: L p = J v /S[(P c -P i ) − σΔπ], where P c is the capillary hydrostatic pressure, P i is the interstitial hydrostatic pressure, σ is the osmotic reflection coefficient, and Δπ is the osmotic pressure difference. Assuming P i was near zero and σΔπ (units = cm-H 2 O) remained constant at 3.78 for 1% BSA Ringer's solution, L p was calculated from the slope of the regression of J v /S on P, where P = (P c − 3.78). This was derived from several occlusions at three different perfusate pressures. Each n signifies that a single vessel was cannulated and the L p serially measured in a single rat, such that an n = 3 means that three different vessels were studied in three different rats. Control studies that document the stability of this model over time and after multiple recannulations of the vessels have been previously reported. 23 
Ischemia-reperfusion Protocol
The protocol was adapted from previous work. 23, 24 In brief, study microvessels were perfused with 1% Ringer/BSA solution for 10 min before baseline L p was assessed. After this assessment, a prolene suture snare was placed around the SMA and tightened for 45 minutes, constituting the gut ischemia phase of the protocol. Cessation of blood flow through the study vessel was confirmed by intravital microscopy. During this time, the bowel was covered with gauze and bathed with a warm Ringer solution. After 45 minutes of ischemia, the prolene suture snare was released and reperfusion of the venule was confirmed and continued for an additional 270 minutes, constituting the reperfusion phase of the protocol. Subsequently, L p was measured at the following time intervals post-SMA occlusion-105 minutes, 165 minutes, 195 minutes, 225 minutes, 255 minutes, 285 minutes, and 315 minutes. Data points were obtained in triplicate at each time interval. For the hydraulic conductivity studies, the reperfusion component of the study lasted 5 hours. For control animals (sham animals), all steps were carried out in the same manner as the appropriate comparison experimental group, except the prolene suture snare around the SMA was not tightened, thereby eliminating the ischemic and reperfusion components of the study. Measures of L p was obtained in the same manner as the other study group animals and serve as time controls.
RNA Interference Studies
Cloning of rat PLSCR1 cDNA: PLSCR1-specific primers were designed from the nucleotide sequences deposited in the Entrez data bank. Blast search confirmed that the region of PLSCR1 to be amplified did not share any appreciable identity with any known genes in the non-redundant or EST database. Total RNA (1 μg) was reverse transcribed using random hexamers in a 20-μL reaction volume and 5 μL of RT mix, used in a 50-μL PCR reaction using PLSCR1-specific primers. The resulting product was analyzed by agarose gel electrophoresis and cloned into a dual-promoter plasmid (pTopoII; Invitrogen Corp., Carlsbad, CA). The cloned product was sequenced to confirm its identity and used to generate double-stranded RNA (dsRNA) for the RNAi studies.
Synthesis of dsRNA: Sense and antisense RNAs were synthesized in vitro using the mega-riboprobe kit (Ambion, TX) from PLSCR1 and control cDNAs cloned in plasmid vectors as described. 25 Equimolar concentrations of sense and antisense RNA were mixed, phenol-extracted and precipitated. The RNA pellet was dissolved in annealing buffer, boiled for 1 minute in a boiling water bath and allowed to cool to 22°C over 16 hours to form dsRNA. For in vivo studies, dsRNA (20 μg) was mixed with 1.5 μL of lipofectAMINE (Invitrogen) and injected directly into the mesentery.
Synthesis of long dsRNA and RT-PCR: RT-PCR was used to amplify PLSCR1 fragment from rat colon RNA using PLSCR1-specific primers (forward primer: 5′-CGCGTCATCC AGAGTGAG-3′, reverse primer: 5′-TATAATCACCCAG-3′) at an annealing temperature of 58°C. The PLSCR1 PCR product was cloned into pTOPO4 vector (Invitrogen) and sequenced to confirm identity. This cloned cDNA was used as a template to transcribe sense and antisense RNAs in vitro using the Megascript RNA kit (Ambion, Austin, TX) according to the manufacturer's specifications and as described previously. 26 A nonspecific 300-bp segment of pBluescript (Stratagene, La Jolla, CA) was similarly transcribed for use as control dsRNA. Double-stranded RNAs (20 μg) for either pBluescript (control RNAi) or PLSCR1 (PLSCR1 RNAi) were mixed with 1.5 μL of Lipofectamine 2000 (Invitrogen) and brought to a volume of 250 μL before being injected into the ileal mesentery. 27 RNAi protocol: After anesthesia was induced using 2% isoflurane and 2% O 2 , a midline incision was made, and the small bowel mesentery was gently exposed as described in the animal preparation section. The dsRNA solutions described above were applied onto the thin mesenteric tissue over a mesenteric arcade containing appropriate venule so as not to disrupt the vascular arcades or mesenteric tissue itself. In addition, the dsRNA solution was injected into the mesenteric fat tissue underneath the same arcade by raising a wheal in that area. The ileal wall underneath the injected arcade was marked with a 6-0 Prolene blue monofilament suture to identify the region with knockdown. The laparotomy incision was then sutured closed in two layers, and the rats were allowed to recover from the anesthesia as described previously. [23] [24] [25] Three days after dsRNA injections, anesthesia was again induced for ischemiareperfusion studies below. The midline laparotomy incision was reopened, and the previously marked ileal loop was exposed again. A suitable postcapillary mesenteric venule in the area in which the dsRNA was previously administered was cannulated and measured for L p at regular intervals (ischemia-reperfusion protocol described above).
Determination of PS Inhibition on L p After IRI
To determine the effect of PS inhibition on L p after IRI, we used several inhibitors of PS exposure (DTE, 2-BP, DIDS). Dithioerythritol is an inhibitor of the cysteine residue that is essential for PLSCR1 translocation; 2-BP is an inhibitor of PLSCR1 trafficking to the plasma membrane, which renders PLSCR-1 nonfunctional; and DIDS is an inhibitor of the anion exchange mechanism necessary for PLSCR1 function. First, we measured L p at baseline (t = 0) and during ischemia (t = 45 minutes). Serial measurements of L p were then obtained in triplicate during reperfusion at the following time intervals: 105 minutes, 165 minutes, 195 minutes, 225 minutes, 255 minutes, 285 minutes, and 315 minutes. The measurements for L p were then compared at baseline, during IRI, and during IRI with pre-ischemia administration of DTE (0.5 nM, n = 3), 2-BP (100 μM, n = 3), DIDS (5 mg/kg, n = 3), DTE + 2-BP + DIDS.
To determine the effect of targeted PS inhibition on L p after IRI, we used RNAi to specifically knockdown PLSCR-1. Three days after the injection of dsRNA for PLSCR1, rats underwent the IRI protocol as described above (n = 3). Next, serial measurements of L p were obtained in triplicate at baseline (t = 0), during ischemia (t = 45 minutes), and during reperfusion at the following time intervals: 105 minutes, 165 minutes, 195 minutes, 225 minutes, 255 minutes, 285 minutes, and 315 minutes. The measurements for L p were then compared at baseline, during IRI, and during IRI after PLSCR1 RNAi.
Finally, we wanted to investigate a potential therapeutic tool, Diannexin, which blocks exposed PS from interacting with proteins that are attracted to the negatively charged moieties of PS, and as such, it is a selective PS blocker. Rats underwent the IRI protocol as described above. Diannexin (400 μg/kg) was administered before SMA occlusion (n = 3), and to simulate a more clinically relevant scenario after SMA occlusion was released (n = 3). Next, serial measurements of L p were obtained in triplicate at baseline (t = 0), during ischemia (t = 45 minutes), and during reperfusion at the following time intervals: 105 minutes, 165 minutes, 195 minutes, 225 minutes, 255 minutes, 285 minutes, and 315 minutes.
Statistical Analysis
Comparisons between control and sample means for in vivo modified Landis calculations were made with single-factor analysis-of-variance. L p test groups differences were compared using the area for the area under the curve (AUC) analysis, which was calculated using the trapezium rule under the Landis curve where the area for each trapezoid = 0.5 Â (b 1 + b 2 ) Â height, where b 1 = L p at t 1 and b 2 = L p at t 2 and height = (t 2 ) − (t 1 ). Differences between measures of L p were evaluated with a paired Student's t test or repeated-measures two-way analysis of variance as appropriate. Tukey's honest significant difference post hoc tests were calculated to verify differences among group comparisons. Percentages are expressed as mean ± SEM based on a normal distribution. P values less than 0.05 were considered statistically significant. Values for L p are expressed as mean ± SEM Â 10
, except when fold increases or percentage change are reported.
RESULTS

Ischemia-reperfusion Studies
The effect of PS inhibition on L p after IRI is displayed in Targeted inhibition with Diannexin had the most prominent effect on L p after IRI, and this is displayed in Figure 3 . Both pre-and post-ischemia Diannexin attenuated the IRI-induced increase in L p at all time points during reperfusion ( p < 0.02). This effect held even for the 45-minute, 165-minute, and 195-minute time points that weren't significantly different in the experiments of inhibition with DTE, 2-BP or DIDS. Diannexin administered pre-ischemia had a slightly more robust effect than Diannexin administered post-ischemia, as pre-ischemia Diannexin returned the IRI-induced increase in L p to baseline levels at the 45-minute and 105-minute periods ( p < 0.05). An AUC analysis was performed for all inhibitors during IRI. With the exception of DTE and DIDS, all agents demonstrated significant attenuation of the IRI-induced increase in L p ( p < 0.001). This is shown in Figure 4 .
DISCUSSION
Endothelial dysfunction promoting extravascular fluid losses can predispose severely injured patients to multiple organ system failure and sepsis. Extravascular fluid loss may be due to loss of the endothelial barrier, in part mediated by PS-exposing cells that serve as an extrinsic signal for phagocytosis. Our hypothesis was that inhibiting PS expression on endothelial cells would attenuate IRI induced increases in L p . In our first specific aim we sought to determine whether inhibitors of PS exposure on endothelial cells in vivo (DTE, 2-BP, and DIDS) would attenuate the increase in L p observed during IRI. In our second specific aim, we sought to determine whether the increase in L p could be attenuated pharmacologically during IRI using targeted inhibition of PS exposure (RNAi and Diannexin). We found that DTE, 2-BP, and DIDS were modestly effective at decreasing L p and that targeted inhibition of PS exposure via RNAi and Diannexin were very effective at reducing L p during IRI. These results add further support that PS exposure is a key event in the pathogenesis of microvascular dysfunction during IRI and suggests that inhibition of PS exposure is a promising strategy that may one day be used to mitigate the effects of IRI.
Our in vivo studies interrogated the production transport, insertion, modification, flipping, and antagonist properties of PLSCR1 (and resultant PS exposure). The compound 2-BP inhibited the transport and insertion of PLSCR1 into the cell membrane, leading to decreased L p . Using the known enzymatic structure and function of PLSCR1, we used thiol modification of the cysteine residues by DTE to interrupt the enzymatic conformational change required for PLSCR1 function, leading to decreased L p . The combined inhibitors approach (2-BP + DTE + DIDS) was inferior to 2-BP alone, possibly due to DTE and DIDS interfering with 2-BP efficacy (decreased uptake or diminished function). The biodegradation of 2-BP by DTE and DIDS, both with some reducing properties, is one hypothetical mechanism of diminished function. Another plausible mechanism would be DTE competing with 2-bromopalmitate for cysteine residues, preferentially undergoing reduction instead of palmitoylation inhibition, exhibiting a weaker effect than 2-BP alone. 28 Another potential mechanism involves modulation of downstream inflammatory mediator production that contributes to endothelial permeability. For example, DIDS has been shown to inhibit serine palmitoyltransferase activity and downstream sphingolipid synthesis, 29 and nuclear sphingolipids propagate genes that are involved in inflammation. 30 As opposed to 2-BP, DIDS may exhibit a dominant effect on palmitoyltransferase activity and downstream sphingolipid production, rendering less of a protective effect compared to 2-BP alone.
With targeted RNAi we were able to significantly attenuate L p due to the decreased production of the PLSCR1 enzyme. Finally, targeted PS inhibition via the specific blocker, Diannexin, significantly decreased the L p observed after IRI when given either before, or after, the initiation of ischemia. Diannexin was more effective than RNAi, possibly due to the completeness of the PS blockade with Diannexin compared to knockdown of PLSCR1 via RNAi or from cells potentially increasing production of PLSCR1 mRNA during progressive IRI. Moreover, the administration of Diannexin before ischemia was more effective compared with Diannexin administration after ischemia, which makes intuitive sense. In the setting of traumatic injury, Diannexin post-ischemia would more closely resemble real-life therapy during the initial injury phase, however, theoretically Diannexin could be administered prophylactically after the initial resuscitation but before an additional systemic insult occurs (such as in the damage control surgery setting before repeated operations) and potentially prevent the sequelae of the second hit phenomenon.
Phosphatidylserine exposure during hypoxia-reoxygenation is associated with microvascular dysfunction. In vitro, hypoxia (2 hours) and reoxygenation (1 hour) in murine endothelial cells is associated with increased extracellular beta-2 glycoprotein binding to endothelium (beta-2 glycoprotein has high affinity for anionic phospholipids such as PS) as demonstrated by increased Annexin-V immunofluorescence. 16 In that study, PLSCR1 mRNA was upregulated in hypoxia-treated cells, and hypoxia with subsequent reoxygenation increased protein expression of PLSCR1. In human umbilical vein endothelial cells, hypoxia and reoxygenation in cells exposing PS by Annexin-V demonstrated increased C3/C5 production and activation. Complement activation increases microvascular dysfunction during reperfusion injury through increased binding and activation of neutrophils. 18 In systemic capillary leak syndrome, endothelial cells exposed to patient sera demonstrated increased PS exposure, DNA fragmentation and increased bax/bcl-2 ratios, 14 suggesting that PS exposure and resultant microvascular leak is associated with endothelial loss via apoptosis. During sepsis, lipopolysaccharide-induced microparticles (small 1-μm vesicles that bud from damaged endothelial cells) exposing PS can cause microvascular dysregulation via endothelial apoptosis, possibly by a nitric oxide intermediate. 31 Microvascular dysfunction and increased endothelial permeability in vivo is associated with PS exposure. 32 In a murine model of pulmonary sepsis, endothelial barrier dysfunction and increased permeability to albumin was associated with increased PS exposure. 33 In terms of quantifying the deleterious nature of PS production and translocation, this study demonstrated a 10-fold increase in exposure of PS, which corresponded to a sixfold increase in apoptosis, a 10-fold increase in pulmonary endothelial cell death and a threefold increase in microvascular fluid leak.
In our current study, L p during IRI was reduced significantly by inhibiting PLSCR1 and PS exposure, suggesting that PS may act through an apoptotic mechanism to produce vascular dysfunction. A limitation of our in vivo studies was an inability to quantify endothelial apoptosis and cite this as the cause for increased L p during IRI in our experiments.
Phosphatidylserine exposure has deleterious effects beyond endothelial apoptosis. Exteriorization of PS is associated with prothrombinase complex formation and recruitment of cells that participate in further inflammation. 34 As thrombosis and permeability are intrinsically linked, shielding PS-rich surfaces decreases catalytic efficiency of tenase and prothrombinase complexes by 200-and 1,000-fold 35 and pharmacologic compounds that act on PS production, trafficking, exteriorization or that modulate PLSCR1 activity may be beneficial. In preclinical models, PS antagonism has been shown to be effective. In a mouse model of bilateral renal IRI, Diannexin pretreatment decreased proximal tubule damage (diminished tubular cast formation), decreased leukocyte influx (decreased granulocyte staining on immunohistochemistry), and decreased neutrophil eliciting factors (reduced mRNA production of KIM-1 and NGAL). Specifically, PS inhibition reduced mRNA markers of acute kidney injury by 62% to 67% and protein expression by 71% to 74%, correlating to mildly damage renal tubules (approximately 1% scattered casts in tubules) in contrast to untreated controls (25% casts in tubules), which improved renal recovery (normalized urine flow and urinary glucose levels). 36 In a model of hepatic ischemia-reperfusion, PS inhibition reduced levels of liver transaminases (80% reduction), and decreased necrosis of liver tissue on hematoxylin-eosin staining. 37 The authors of both studies concluded that PS inhibition via Diannexin blocked leukocyte activation and recruitment, limiting inflammation in the renal and hepatic microcirculation, preserving parenchymal function.
In conclusion, microvascular dysfunction after IRI is in part linked to endothelial cells with increased levels of PS exposed on their cell surfaces which promotes inflammation and injury. Plausible therapeutic targets exist for targeting both intracellular and extracellular mechanisms of inhibiting PS exposure. Further studies on the intracellular mechanistic aspects of PS exposure in endothelial cells and the impact on microvascular dysfunction are warranted. AUTHORSHIP A.S., A.B., and G.P.V. participated in study design, data acquisition and analysis and composition of the article.
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Dr. William G. Cioffi (Providence, Rhode Island): Dr. Kozar and members and guests. I want to first congratulate the authors on a really elegant set of studies and even a better presentation. Great slides.
The authors have extended both their and others' work which have demonstrated the role of phosphatidylserine or PS in ischemia reperfusion injury.
There is an extensive amount of literature highlighting the role of membrane PS in promoting apoptosis in a variety of settings and a variety of cells.
They have also capitalized on the availability of a variety of both blockers and inhibitors of Scramblase and PS.
The strengths of this study are their use of both their in vitro and in vivo models, as well as the multiple methods to both selectively and non-selectively inhibit and block Scramblase and bind phosphatidylserine. The results are believable and fit with the current literature.
I have a couple of methodological questions and one question of clinical relevance.
Ischemia reperfusion results in PS migration in multiple cell types. In your in vivo model how do you know that the effects that you saw were actually due to the effects on the endothelial cells. Since translocated PS is pro-apoptotic, why didn't you measure endothelial apoptosis?
In your in vitro model you're using anoxia instead of hypoxia. Does this matter? Did you try hypoxia and did you get the same results?
In your in vivo data 2VP, as you noted, was more effective alone than when combined with DTE and DIDS. You mentioned that in your presentation but please comment on why do you think that happened?
Why did you pick the endpoints that you did? How much reduction in PS translocation and production is clinically relevant?
In the same vein, in your in vivo model you demonstrate a significant reduction in LP but is it relevant? Do you have direct measurements of decreased edema formation?
Finally, Diannexin or Annexin-V has been around for decades. There was an extensive amount of research and even clinical trials in transplant about five years ago. What happened to these trials? I searched for them online, couldn't find the results and couldn't find whether the drug is still available or was taken off the market due to untoward effects.
Again, this is a great set of experiments. Well done. Well presented. And I thank the association for the privilege of the floor.
Dr. H. Gill Cryer (Los Angeles, California): Yes, thank you. Really a terrific study. Some years ago, many, actually, we used Diannexin in a microcirculation model, an in vivo microcirculation model.
And the ischemia reperfusion in the intestine, like you showed, would cause rolling of white cells, really rather dramatic in the post-capillary venules. And if you gave Diannexin it would obliterate that.
And I noticed in the way that you were measuring your permeability with the cell column did you have sticking white cells within those venules when you were doing those measurements? And did it make any difference if they were or weren't there when you gave the Diannexin? With respect to adherent white cells and Diannexin. Our group recently published a paper in the American Journal of Physiology demonstrating two discrete peaks during ischemia reperfusion. The first peak is probably related to reactive oxygenation species production. In our experiments we fed rats a known inhibitor of reactive oxygen species production (xanthine oxidase), which was shown to block production and attenuate permeability during phase 1. The second phase, which is much more profound with respect to microvascular permeability, is most likely due to white blood cell adhesion. We interpret upregulation of ICAM-1 as an indication that neutrophils are adhering and degranulating during the second phase of reperfusion. So while we didn't directly visualize or assay Diannexin effects with respect to white blood adhesion, we infer from our previous data that neutrophil-mediated permeability affects are occurring and being blocked by Diannexin at the microvascular level.
How much PS matters? I think that's an ongoing clinical question and we don't have an exact answer. Few studies have quantified PS clinically, however there are several mechanisms that can cause injury. We know for example that PS exposure is intrinsically linked to coagulation via endothelial exposure of PS and elicitation of surface-rich PS-exposing microparticles. These microparticles go on to produce downstream thrombosis and inflammation, which cause adverse clinical sequelae.
With respect to non-specific inhibition of scramblase and the choice of experimental compounds. It's important to mention that 2-BP, DTE and DIDS were chosen for mechanistic qualities, not for therapeutic qualities. And with respect to differences when we used a combined approach as opposed to 2-BP alone, there are several possibilities. There may be an element of DTE and DIDS causing direct damage to endothelial cells, thereby preventing 2BP from achieving its function in the nucleus. It potentially damages the nucleus directly or prohibits 2-BP from being absorbed intracellularly. DTE and DIDS may also be degrading 2-BP, limiting its effects.
Did we check hypoxia as opposed to anoxia? Yes, we conducted cell culture studies with hypoxia but our permeability effects were obviously much more profound with the anoxia. Moreover, we believe that anoxia is more clinically relevant. We felt that anoxia-reoxygenation coupled better with the in vivo experiments, simulating an anoxic environment to the intestinal endothelium via complete SMA occlusion.
Finally, with respect to endothelial apoptosis. We didn't do TUNEL staining to measure endothelial apoptosis so we cannot directly quantify how much PS was exposed and how much our cells were dying. Scramblase, however, has been around for a long time as a known enzyme involved in apoptosis. The results of this study sets the stage to make the argument that apoptosis is a plausible mechanism of injury and as such, the involvement of apoptosis will be the focus of future studies.
Again, I would like to thank everybody, principally my career mentor, Dr. Greg Victorino, for the opportunity to participate in this research.
